Clinical Trial Update: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a carboplatin, eribulin, and veliparib combination in stage IV breast and ovarian cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Halaven (eribulin)
• Veliparib (veliparib)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Breast Cancer Stage IV, Ovarian Cancer | Phase 2 | Status: WITHDRAWN